论文部分内容阅读
目的 探讨灯盏花素与LY333531对糖尿病大鼠肾脏的保护作用。方法 建立链脲佐菌素(STZ)诱导的大鼠糖尿病模型,随机分为对照组、模型组、灯盏花素组(20 mg·kg-1·d-1,灌胃)与LY333531组(10 mg·kg-1·d-1,灌胃)。8周末检测肾组织及尿丙二醛(MDA)含量,肾组织抗氧化酶与蛋白激酶C(PKC)活性;观察肾小球病理形态及免疫组化变化。结果 给药组大鼠肾重、肾重／体重、24 h尿白蛋白排泄率(AER)、肾小球面积、肾小球容量及系膜区面积均明显低于模型组(P<0.05)。模型组肾组织及尿MDA含量明显高于对照组(P<0.01);肾组织超氧化物歧化酶(SOD)、过氧化氢酶(CAT)与谷胱苷肽过氧化物酶(GSH-PX)活性明显低于对照组(P<0 05,P<0.01);两给药组这些变化明显缓解(P<0.05)。模型组肾组织PKC活性明显高于对照组(P<0.01),两给药组肾组织PKC活性明显低于模型组(P<0.05)。模型组肾小球转化生长因子β1(TGF-β1)与结缔组织生长因子(CTGF)表达明显高于对照组(P<0.01),两给药组这些改变明显减轻(P<0.05)。结论灯盏花素与LY333531对糖尿病大鼠肾脏有明显保护作用,其机制可能部分与抑制肾组织TGF-β1与CTGF过高表达有关。
Objective To investigate the protective effect of breviscapine and LY333531 on the kidney of diabetic rats. Methods Streptozotocin (STZ) -induced diabetic rat model was established and randomly divided into control group, model group, breviscapine group (20 mg · kg-1 · d-1, intragastrically) and LY333531 group mg · kg -1 · d -1, intragastrically). At the end of the 8th week, the content of malondialdehyde (MDA), the activity of antioxidant enzymes and protein kinase C (PKC) in kidney were measured. The pathological changes of glomerulus and the changes of immunohistochemistry were observed. Results The renal weight, kidney weight / body weight, urinary albumin excretion rate (AER), glomerular area, glomerular volume and mesangial area in the treatment group were significantly lower than those in the model group (P <0.05) . The content of MDA in renal tissue and urine in model group was significantly higher than that in control group (P <0.01). The activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase ) Activity was significantly lower than the control group (P <0.05, P <0.01); these two groups were significantly alleviated (P <0.05). The PKC activity in renal tissue in model group was significantly higher than that in control group (P <0.01). The PKC activity in renal tissue in both groups was significantly lower than that in model group (P <0.05). The expression of TGF-β1 and CTGF in model group was significantly higher than that in control group (P <0.01), and the changes in both groups were significantly reduced (P <0.05). Conclusion Breviscapine and LY333531 have significant protective effects on the kidney of diabetic rats, which may partly be related to the inhibition of TGF-β1 and CTGF overexpression in renal tissues.